Modern blood cancer treatments require new approach for monitoring, reporting side effects

June 13, 2018, Lancet

Treatment changes including the advent of targeted and immune therapies have dramatically improved survival for blood cancers, but new report calls for improved evaluation of poorly understood side effects that may develop over time.—-

Survival rates for blood cancers—including lymphoma, myeloma and some types of leukaemia—have dramatically increased over the past decade, due in great part to novel treatment approaches including molecularly-targeted therapies and immunotherapies.

In contrast to traditional forms of treatment which were largely episodic and finite (ie, a set number of cycles of intravenous chemotherapy), for some haematological cancers may now be given continuously over years, or in some cases indefinitely.

However, a new Commission by The Lancet Haematology shows how current methods of reporting adverse events, focused on assessing a drug or regimen's safety, often fail to also appropriately identify important delayed, chronic or cumulative effects that can affect substantially.

In particular, the toxicity over time and tolerability to the patient of new chronic or continuously administered therapies are not well defined, and are poorly captured by existing reporting mechanisms.

The Commission brings together 40 leading clinicians, clinical investigators, regulators, biostatisticians and patient advocates to analyse the evidence and propose recommendations to policy makers, researchers, industry and regulators, and will be launched at the European Haematological Association meeting in Stockholm.

"The success in outcomes and survival in many haematological malignancies is historically unparalleled and fuelled by scientific discovery and implementation. Patients are now living with the challenge of managing not just their haematological malignancy, but also managing chronic therapy for their illness, with new types of acute, chronic, cumulative and late toxicities. Measures to address the broad facets of toxicity assessment must be prioritised and further developed to ultimately enhance accurate, comprehensive, patient-centred toxicity reporting that will meaningfully inform the care of patients with ," says Commission Chair Dr. Gita Thanarajasingam, Mayo Clinic, Rochester (MN).

The authors propose new approaches to evaluating and reporting adverse events to complement the current methods. These include expanding reporting beyond high grade, acute toxic side-effects, and capturing less severe but chronic side effects, and cumulative and late effects in a more standardized manner. While short term side effects with some regimens might include nausea and vomiting occurring over a few days in a cycle, long term effects might include neuropathy which worsens over time with ongoing drug exposure and can persist even after therapy is complete, for example.

Additionally, the authors emphasize that changes to clinical trial design to accommodate delayed adverse events, and incorporating patient reported outcomes into trials to assess and improve tolerability, adherence and quality of life are essential.

The Commission also examines streamlined approaches to identify unexpected side effects from stem cell transplantation and improved evaluation of late and long term side effects in survivors. As newer treatments in haematological malignancies are offered more widely, capturing data from population studies will be essential to understand side effects outside of clinical trial settings. Additionally, post-marketing surveillance by regulatory agencies should adapt to include relevant data on long-term in a real world patient population.

Explore further: Reporting of adverse events in targeted therapy and immunotherapy trials is 'suboptimal'

More information: The Lancet Haematology, www.thelancet.com/journals/lan … (18)30051-6/fulltext

Related Stories

Reporting of adverse events in targeted therapy and immunotherapy trials is 'suboptimal'

October 5, 2016
A significant number of trials of targeted therapies and immunotherapies in recent years show suboptimal reporting of adverse events, particularly the reporting of recurrent or late toxicities and the duration of the adverse ...

Evaluating pediatric leukemia treatment

April 12, 2018
A drug called dasatinib was found to be safe and effective for children with chronic myeloid leukemia, according to a clinical trial published in the Journal of Clinical Oncology.

Trial confirms pelvic radiation as standard of care for high-risk endometrial cancer

September 25, 2017
In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I-II high-risk endometrial cancer were not superior following vaginal ...

Combined therapies increase side effects for patients with advanced breast cancer

November 2, 2017
Lisbon, Portugal: Patients with advanced breast cancer who are treated with a combination of drugs that target specific molecules important for cancer development and also the hormones that are driving it are at increased ...

Halving radiation therapy for HPV-related throat cancer offers fewer side effects, similar outcomes

September 25, 2017
Mayo Clinic researchers have found that a 50 percent reduction in the intensity and dose of radiation therapy for patients with HPV-related throat cancer reduced side effects with no loss in survival and no decrease in cure ...

Measuring patients' muscles to predict chemotherapy side effects

February 22, 2017
Chemotherapy has long been standard treatment for many cancers, but its clinical benefits can also come with well-documented side effects. Doctors say the challenge is knowing which patients will experience these side effects, ...

Recommended for you

First immunotherapy success for triple-negative breast cancer

October 21, 2018
There is new hope for people with an aggressive type of breast cancer, as an immunotherapy trial shows for the first time that lives can be extended in people with triple-negative breast cancer.

Healthy diets linked to better outcomes in colorectal cancer

October 20, 2018
Colorectal cancer patients who followed healthy diets had a lower risk of death from colorectal cancer and all causes, even those who improved their diets after being diagnosed, according to a new American Cancer Society ...

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.